Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Alpelisib Arrives as New Targeted Option for Breast Cancer Subgroup

August 20th 2019

Dejan Juric, MD, discusses the significance of the alpelisib approval and the importance of developing a plan for the management of adverse events.

Resistance Shapes New Therapeutic Options in ER-Positive Breast Cancer

August 19th 2019

Although hormonal manipulation was an established part of breast cancer treatment long before the underlying biology of the disease was characterized, advancements in the understanding of estrogen receptor signaling are rapidly changing the therapeutic landscape.

Dr. Goetz on Treatment Challenges for ESR1-Mutant Breast Cancer

August 16th 2019

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the treatment landscape of estrogen receptor (ER)–positive breast cancer and advances made within the last 5 years.

Pivotal Trials With CDK4/6, PI3K Inhibitors Propel Progress in HR+ Breast Cancer

August 15th 2019

Leticia Varella, MD, discusses the progression of available treatments in hormone receptor-positive, HER2-negative metastatic breast cancer.

Top Breast Cancer Oncologists Highlight Their Ongoing Research

August 8th 2019

Experts from Emory University School of Medicine, Massachusetts General Hospital, and Hospital of the University of Pennsylvania, highlight the exciting research being conducted at their respective institutions.

Encequidar Plus Oral Paclitaxel Increases Response Over IV Paclitaxel in Breast Cancer

August 8th 2019

The combination of encequidar and oral paclitaxel improved the overall response rate compared with IV paclitaxel in patients with metastatic breast cancer.

Genomic Assays Answer Adjuvant Questions in Early-Stage Breast Cancer

August 7th 2019

Alan B. Astrow, MD, discusses the latest efforts to personalize patient care in early-stage, HR-positive, HER2-negative breast cancer.

CDK4/6 Inhibitors Showing Survival Gains in Metastatic HR+ Breast Cancer

August 6th 2019

Payal D. Shah, MD, discusses the paradigm shift in metastatic HR-positive, HER2-negative breast cancer, now largely defined by the use of CDK4/6 inhibitors.

IMpassion130 Trial Takes Immunotherapy to Forefront of TNBC

August 6th 2019

Eleni Andreopoulou, MD, discusses the impact of the IMpassion130 trial on TNBC treatment and the use of immunotherapy in this patient population.

Dr. Andreopoulou on the Impact of Immunotherapy in TNBC

August 5th 2019

Eleni Andreopoulou, MD, associate professor of clinical medicine, Weill Cornell Medical College, associate attending physician, NewYork-Presbyterian Hospital, discusses shifts in the treatment paradigm of metastatic triple-negative breast cancer (TNBC) and the impact immunotherapy has had in the field.

Experts Discuss Highly Anticipated Study Results Across Tumor Types

August 5th 2019

OncLive interviewed experts at the State of the Science Summits in July 2019 on highly anticipated clinical trial results across tumor types.

Genetic Variant Causes Susceptibility to TNBC in African Subpopulations

August 2nd 2019

Lisa Newman, MD, MPH, FACS, FASCO, highlights the history and ongoing research of the genotype causing predisposition to TNBC in African-American women.

Dr. Meisel on Optimizing Genomic Assays in Early-Stage HR-Positive, HER2-Negative Breast Cancer

August 1st 2019

Jane L. Meisel, MD, an assistant professor, Department of Hematology and Medical Oncology and Department of Gynecology & Obstetrics, Winship Cancer Institute, Emory University School of Medicine, discusses optimizing genomic assays in early-stage hormone receptor (HR)–positive, HER2-negative breast cancer.

Immunotherapy Builds Momentum in Metastatic TNBC

July 31st 2019

Aditya Bardia, MD, MPH, discusses the recent momentum in metastatic triple-negative breast cancer treatment.

Ribociclib Improves Survival in Postmenopausal Women With Advanced Breast Cancer

July 31st 2019

Adding the CDK4/6 inhibitor ribociclib to fulvestrant significantly improved overall survival as a first- or second-line treatment for postmenopausal women with hormone receptor–positive/HER2-negative breast cancer, according to findings from a preplanned interim analysis of the phase III MONALEESA-3 trial.

Perusing Breakthroughs in Breast Cancer in Pasadena

July 31st 2019

We traveled to Pasadena, California, for a State of the Science Summit™ on Breast Cancer, which featured insights from the faculty from City of Hope.

Precision Medicine Advances in HR+/HER2- Breast Cancer

July 30th 2019

Jane Meisel, MD, provides insight on how genomic assays are helping to individualize treatment plans and strategies to determine the optimal duration of endocrine therapy.

Abemaciclib/Fulvestrant Combo Improves OS in HR+ Advanced Breast Cancer

July 30th 2019

Abemaciclib plus fulvestrant improved overall survival in patients with hormone receptor–positive, HER2-negative breast cancer.

Pembrolizumab Combo Improves pCR in Locally Advanced TNBC

July 29th 2019

Pembrolizumab in combination with chemotherapy led to a statistically significant improvement in pathological complete response rates compared with placebo plus chemotherapy in the neoadjuvant phase of a neoadjuvant/adjuvant treatment regimen in patients with triple-negative breast cancer, meeting one of the dual primary endpoints of the phase III KEYNOTE-522 trial.

How CDK4/6 Inhibitors Are Shaking Up the Breast Cancer Paradigm

July 28th 2019

During a recent OncLive Peer Exchange®, a panel of breast cancer experts discussed how they are using CDK4/6 inhibitors in their practices. They shared their insights on the tolerability and toxicity profiles of the FDA-approved CDK4/6 inhibitors, how they choose which agents to use for each patient, and how they select the next line of therapy after the patient progresses.